LIGAND PHARMACEUTICALS INCORPORATED Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss
LIGAND PHARMACEUTICALS INCORPORATED (LGND) had Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss of $162.00 thousand as of 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Notes › Credit Losses › ASU 2016-13 Transition
us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss · last filed 2023-02-28
- 2022-12-31: Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss $162.00K.
- 2021-12-31: Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss $94.00K.
- 2020-12-31: Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss $3.00K.
- 2019-12-31: Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss $19.00K.
| Period end | Debt Securities, Held-to-maturity, Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2022-12-31 | $162.00K 10-K · filed 2023-02-28 |
| 2021-12-31 | $94.00K 10-K · filed 2023-02-28 |
| 2020-12-31 | $3.00K 10-K · filed 2022-02-28 |
| 2019-12-31 | $19.00K 10-K · filed 2021-02-24 |